Related Experiment Videos

Cell death markers in patients with cirrhosis and acute decompensation

Stewart Macdonald1, Fausto Andreola1, Patrik Bachtiger1

  • 1Liver Failure Group, Institute for Liver and Digestive Health, University College London, London, United Kingdom.

Insights

Cell death markers, caspase-cleaved keratin 18 (cK18) and keratin 18 (K18), increase with cirrhosis severity. Non-apoptotic cell death is prominent in acute decompensation (AD) and acute on chronic liver failure (ACLF).

Area of Science:

  • Hepatology
  • Cellular Biology
  • Biomarker Discovery

Background:

  • Cirrhosis progression to acute decompensation (AD) and acute on chronic liver failure (ACLF) involves complex pathophysiology.
  • Understanding the role of cell death is crucial for managing liver disease severity and outcomes.
  • Plasma-based biomarkers offer a non-invasive approach to assess cellular processes in liver disease.

Purpose of the Study:

  • To investigate the role of cell death in patients with cirrhosis experiencing AD and ACLF.
  • To evaluate plasma biomarkers of apoptosis and total cell death, specifically caspase-cleaved keratin 18 (cK18) and keratin 18 (K18).
  • To correlate cell death markers with disease severity, clinical parameters, and predict progression from AD to ACLF.

Main Methods:

  • Analysis of plasma samples from the CANONIC study cohort (N=337), including AD and ACLF patients, healthy volunteers, and stable cirrhosis patients.
  • Measurement of cK18 and K18 using enzyme-linked immunosorbent assay (ELISA) to determine apoptotic and total cell death.
  • Histological confirmation of hepatic cell death using Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining in a subset of AD patients.

Main Results:

  • Plasma concentrations of cK18 and K18 significantly increased, while the cK18:K18 apoptotic index decreased with increasing AD and ACLF severity.
  • Increased cell death markers were associated with alcohol etiology and prior history of alcohol abuse, but not underlying infection.
  • Cell death markers correlated with systemic inflammation and hepatic failure markers (ALT, bilirubin) but not extrahepatic organ injury.

Conclusions:

  • Hepatic cell death is a significant feature of AD and ACLF, with its magnitude correlating with clinical severity.
  • Non-apoptotic cell death pathways become predominant as AD and ACLF severity increases.
  • Cell death markers, including cK18 and K18, improve the predictive performance of the CLIF-C AD score for AD to ACLF progression.

Related Concept Videos